TP53 and colorectal carcinoma: For experimental validation, we treated the syngeneic pairs of p53 wt and p53 knockout HCT116, RKO and SW48 CRC cell lines with the p53-activator Nutlin-3a, a small-molecule compound antagonizing the inhibitory interaction of MDM2 with p53 26.